Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Pain. 2022 Nov 14;164(6):1340–1354. doi: 10.1097/j.pain.0000000000002824

Figure 9: 3-oxa-PD1 inhibits spinal production of LCN2 production in CTCL mice and LCN2 secretion in astrocyte cultures.

Figure 9:

(A, B) Intrathecal injection of 3-oxa-PD1 (100 ng, A) inhibited LCN2 production in cervical and lumbar segment of spinal cord in CTCL mice. Two-way ANOVA with Bonferroni’s post hoc test. F (1, 28) = 27.17, P < 0.0001. n = 8 per group. (C, D) Intraperitoneal injection of 3-oxa-PD1 (300 ng, C) inhibited LCN2 production in cervical and lumbar segment of spinal cord in CTCL mice. Note that LCN2 level is very low in naïve animals and substantially increased in CTCL mice. Two-way ANOVA with Bonferroni’s post hoc test. F (1, 28) = 27.17, P<0.0001. Spinal cord tissues were collected 3 h after 3-oxa-PD1 administration on CTCL Day 45. n = 8 per group. (E, F) 3-oxa-PD1 treatment in primary cultures of astrocytes (E) inhibited LCN2 secretion in culture medium. One-way ANOVA with Bonferroni’s post hoc test. F (2, 42) = 89.62, P<0.0001. n = 6 per group. LCN2 levels were measured by ELISA using commercial kits. Data are shown as mean ± SEM.